Secundum ad miningweekly, Anglo American, diversificatur Mining et Sales Company, is cooperantem cum Umicore ut develop a technology per eius Anglo American Platinum (Anglo American Platinum est condita, et cella cell vehicles (FCEV) provide potestatem.
Anglo American coetus dixit in Lunae quod freti in hac technology, ibi erit non opus est aedificare hydrogenii infrastructure et supplementum cibus retiacula, et transmissio, repono et hydrogenation facilities est considerari unum de pelagus impedimenta et hydrogenation facilities est considerari unum de pelagus impedimenta et hydrogenation facilities est considerari unum de pelagus impedimenta et hydrogenation facilities est considerari unum de pelagus impedimenta et hydrogenation facilities est considerari unum de pelagus impedimenta et Hydrogenation Clean Hydrogenii.
Hoc iuncturam investigationis et progressionem consilii tendit ad ulterius progressus processus chemica vinculum hydrogenii ad liquorem (sic-dicitur liquido organicum hydrogenii carrier vel Lohc, liquido organicum hydrogenii carrier vel LOCHC, Liquid Usus Fuel CELLA (FCEV) et Aliae Vehicles secundum Catalyst technology ad platinum coetus metalla.
Usus LOHC dat hydrogenii processionaliter et transportari per conventional liquida transportation pipelines ut oleum tanks et pipelines, sicut PETROLEUM aut gasoline, sine necessitate pro complicated facilities ad Gas compress. Hoc vitat nova hydrogenii industria infrastructure et accelerat ad promotionem hydrogenii sicut clean cibus. Cum auxilio novi technology developed ab Anglo American et Umicore, quod potest ducere hydrogenii a LOHC ad electrica vehicles ad inferiorem temperatus et pressura (vocatur dehydrogenation step.
Benny Oeyen, Director of Anglo American scriptor Platinum Group metalla foro progressionem department, introduced quam LOHC technology praebet attractivam, emissionem, liberum et humilis-cost hydrogenium cibus translationem modum. In comitatu credit quod Platinum Group metalla habent specialis catalytic proprietatibus. Auxilium Simplify Logistics et faciam illud magis convenient ad users. Praeterea, supplementa cibus est ut ieiunium quod gasoline vel pellentesque, et habet similis cruisare range, cum reducendo sumptus totius valorem catenam.
Per provectus LOHC Dehydrogenation catalytic technology et usum hydrogenii portans LOHC ad potestatem mobile applications, potest solvere difficultates ab hydrogenii infrastructure et logistics et accelerate a Hydrogenii Infrastructure et logistics et accelerate a FCEV. Lothar Moosman, Senior Vice Praeses, Umicore Nova Business Department (Lotharius Mussmann) dixit. Mohoseman scriptor Company est a elit de Proton Exchange membrana FCev Catalysts.
Anglo American coetus semper fuit unus ex primis fautores de hydrogenii oeconomia et intelligit opportuna positus hydrogenii in viridi industria et mundus translationem. "Platinum Group metalla potest providere maxime momenti catalysts ad viridis hydrogenii productio et hydrogenii-fueled translationem et alia related technologies. Nos exploratores technologiae in area creare diu terminus investment environment ut plene utitur in potential hydrogenii ", CEO Anglo Platinum Tasha Viljoen (Natascha Viljoen) dixit.
Cum enim auxilium Anglo American Platinum Group metalla foro progressionem quadrigis et auxilium de Petri Wassescheid, professor ad University of Erlangen et cooperatores conditor Hydrogenio LOCHC technology, Umicore et portare hoc investigationis. Hydrogenious est princeps in LOHC industria et quoque a portfolio comitatu de ap ausus, an independens venture capitis fiscus societatis invested ab Anglo American coetus. Et principalis investment directiones sunt hydrogenii productio, repono, et translationem.
Anglo American Group scriptor Platinum Group metalla foro progressionem quadrigis scriptor negotium est ut develop et robora novum finem applications de Platinum Group metalla. Haec includit mundus et sustineri industria solutions, cibus cellulis ad electrica vehicles, viridi hydrogenii productio et translationem, Vinyl absorbentium, quod extend in fasciae vita cancer therapies.